Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Cancer immunotherapy in patients with brain metastases

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Exercise and cancer: from "healthy" to "therapeutic"?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. PD-L1-specific T cells

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Rare cause of spontaneous haemothorax: mediastinal and distant lymph node metastases from uveal melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Michael Friedrich
  • Simon Jasinski-Bergner
  • Maria-Filothei Lazaridou
  • Karthikeyan Subbarayan
  • Chiara Massa
  • Sandy Tretbar
  • Anja Mueller
  • Diana Handke
  • Katharina Biehl
  • Jürgen Bukur
  • Marco Donia
  • Ofer Mandelboim
  • Barbara Seliger
Vis graf over relationer

Immunotherapy aims to activate the immune system to fight cancer in a very specific and targeted manner. Despite the success of different immunotherapeutic strategies, in particular antibodies directed against checkpoints as well as adoptive T-cell therapy, the response of patients is limited in different types of cancers. This attributes to escape of the tumor from immune surveillance and development of acquired resistances during therapy. In this review, the different evasion and resistance mechanisms that limit the efficacy of immunotherapies targeting tumor-associated antigens presented by major histocompatibility complex molecules on the surface of the malignant cells are summarized. Overcoming these escape mechanisms is a great challenge, but might lead to a better clinical outcome of patients and is therefore currently a major focus of research.

OriginalsprogEngelsk
TidsskriftCancer immunology, immunotherapy : CII
ISSN0340-7004
DOI
StatusE-pub ahead of print - 3 aug. 2019

ID: 57730672